Yannis Paloyelis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yannis Paloyelis has a total of 643 co-authors. Here are the top co-authors by number of shared publications:
Daniel Martins
Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King’s College London
11 shared publications- Philip Asherson
King’s College London
11 shared publications - Daniel Martins
Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
10 shared publications - Jonna Kuntsi
Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
10 shared publications - Steve Charles Rees Williams
Department of Neuroimaging Institute of Psychiatry, Psychology and Neuroscience King's College London London UK
9 shared publications - Aikaterini Fotopoulou
Department of Clinical, Educational and Health Psychology, University College London, UK
8 shared publications
Latest Publications
- Open Access
Design of Experiments (DoE)‐Optimized Polymeric Oxytocin Nanoparticles for Enhanced Nose‐to‐Brain Delivery
Oxytocin (OT) is a promising candidate for regulating social behavior in autism spectrum disorder (ASD). However, its inconsistent efficacy can be attributed to the lack of an efficient delivery system that selectively target the brain without inducing peripheral side effects following intranasal (IN) administration. In this study, OT is encapsulated within an FDA‐approved poly (lactic‐co‐glycolic acid) (PLGA) nanoparticles (OT‐NP) to improve nose‐to‐brain (NTB) delivery. A PEGylated version (OT‐NP‐PEG) is developed to improve nasal mucosal diffusion. Optimization using a design of experiments (DoE) approach produced nanoparticles with hydrodynamic diameters of ≈93–116 nm, polydispersity index ≈0.20, zeta potential –21 to –33 mV, and drug loading ≈2.8–3.5% (w/w). The stable OT‐NP‐PEG showed sustained release (>42% and 58% at 24 and 72 h) and greater diffusion through simulated nasal mucus. [ 14 C] OT is synthesized with chemical and radiochemical yields of 74% and 53%, respectively. Following IN administration in mice, [ 14 C] OT‐NP‐PEG demonstrated rapid brain uptake, particularly in the olfactory bulb and frontal cortex, with reduced blood and liver exposure compared with free [ 14 C] OT. Finally, IN OT‐NP‐PEG significantly increased self‐grooming frequency in mice, indicating maintained bioactivity and behavioral effects. Overall, OT‐NP‐PEG offers a rationally designed nanoplatform for brain‐targeted OT delivery in ASD and other neuropsychiatric disorders.
Open AccessDesign of Experiments (DoE)‐Optimized Polymeric Oxytocin Nanoparticles for Enhanced Nose‐to‐Brain Delivery
Oxytocin (OT) is a promising candidate for regulating social behavior in autism spectrum disorder (ASD). However, its inconsistent efficacy can be attributed to the lack of an efficient delivery system that selectively target the brain without inducing peripheral side effects following intranasal (IN) administration. In this study, OT is encapsulated within an FDA‐approved poly (lactic‐co‐glycolic acid) (PLGA) nanoparticles (OT‐NP) to improve nose‐to‐brain (NTB) delivery. A PEGylated version (OT‐NP‐PEG) is developed to improve nasal mucosal diffusion. Optimization using a design of experiments (DoE) approach produced nanoparticles with hydrodynamic diameters of ≈93–116 nm, polydispersity index ≈0.20, zeta potential –21 to –33 mV, and drug loading ≈2.8–3.5% (w/w). The stable OT‐NP‐PEG showed sustained release (>42% and 58% at 24 and 72 h) and greater diffusion through simulated nasal mucus. [ 14 C] OT is synthesized with chemical and radiochemical yields of 74% and 53%, respectively. Following IN administration in mice, [ 14 C] OT‐NP‐PEG demonstrated rapid brain uptake, particularly in the olfactory bulb and frontal cortex, with reduced blood and liver exposure compared with free [ 14 C] OT. Finally, IN OT‐NP‐PEG significantly increased self‐grooming frequency in mice, indicating maintained bioactivity and behavioral effects. Overall, OT‐NP‐PEG offers a rationally designed nanoplatform for brain‐targeted OT delivery in ASD and other neuropsychiatric disorders.
- Open Access
- 7 May 2025
- Published by Springer Nature in Research Square
Brain Responses during Anticipation and Consumption of Palatable Food in Women with and without Bulimia Nervosa or Binge Eating Disorder: disorder-related changes and modulation by intranasal oxytocin
Background: Bulimia nervosa (BN) and binge eating disorder (BED) are marked by recurrent episodes of binge-eating despite negative consequences. Although dysregulated reward processing has been proposed as a key mechanism, experimental evidence has been inconsistent. Intranasal oxytocin (OT), a neuropeptide involved in reward modulation and appetite regulation has been suggested as a potential treatment; however, its neurobiological effects remain unclear. This study examined brain responses during palatable food anticipation and consumption in BN/BED patients versus healthy controls and evaluated OT’s modulatory impact. Methods: In a randomized, double-blind, placebo-controlled, crossover fMRI study, 24 women with BN/BED and 23 healthy controls received 40 IU of intranasal OT or placebo prior to scanning. During fMRI, participants experienced both anticipation and receipt of palatable (chocolate milk) and neutral (water) stimuli while providing subjective ratings of pleasantness, intensity, and anxiety. Effects of diagnosis, treatment, and their interaction were analyzed using both frequentist and Bayesian methods. Results: Compared with controls, BN/BED participants rated both stimuli as less pleasant and more anxiety-provoking. fMRI revealed significantly greater insula activation during palatable food receipt in BN/BED. In contrast, nucleus accumbens activity did not differ between groups. OT suppressed hypothalamic responses to palatable taste across groups, without significantly affecting behavioral ratings or other regions. Conclusion: These findings challenge the view that binge eating is solely driven by reward dysfunction and highlight a potential role for altered sensory/interoceptive processing in BN/BED. Although OT modulated hypothalamic activity, its broader clinical utility remains uncertain, warranting further dose-response studies to determine clinical efficacy.
- 7 May 2025
- Published by Springer Nature in Research Square
Open AccessBrain Responses during Anticipation and Consumption of Palatable Food in Women with and without Bulimia Nervosa or Binge Eating Disorder: disorder-related changes and modulation by intranasal oxytocin
Background: Bulimia nervosa (BN) and binge eating disorder (BED) are marked by recurrent episodes of binge-eating despite negative consequences. Although dysregulated reward processing has been proposed as a key mechanism, experimental evidence has been inconsistent. Intranasal oxytocin (OT), a neuropeptide involved in reward modulation and appetite regulation has been suggested as a potential treatment; however, its neurobiological effects remain unclear. This study examined brain responses during palatable food anticipation and consumption in BN/BED patients versus healthy controls and evaluated OT’s modulatory impact. Methods: In a randomized, double-blind, placebo-controlled, crossover fMRI study, 24 women with BN/BED and 23 healthy controls received 40 IU of intranasal OT or placebo prior to scanning. During fMRI, participants experienced both anticipation and receipt of palatable (chocolate milk) and neutral (water) stimuli while providing subjective ratings of pleasantness, intensity, and anxiety. Effects of diagnosis, treatment, and their interaction were analyzed using both frequentist and Bayesian methods. Results: Compared with controls, BN/BED participants rated both stimuli as less pleasant and more anxiety-provoking. fMRI revealed significantly greater insula activation during palatable food receipt in BN/BED. In contrast, nucleus accumbens activity did not differ between groups. OT suppressed hypothalamic responses to palatable taste across groups, without significantly affecting behavioral ratings or other regions. Conclusion: These findings challenge the view that binge eating is solely driven by reward dysfunction and highlight a potential role for altered sensory/interoceptive processing in BN/BED. Although OT modulated hypothalamic activity, its broader clinical utility remains uncertain, warranting further dose-response studies to determine clinical efficacy.
- Open Access
Resting-state brain function and its modulation by intranasal oxytocin in antisocial personality disorder with and without psychopathy
Behavioural, structural and functional neuroimaging differences have been demonstrated between individuals with antisocial personality disorder with (ASPD+P) or without psychopathy (ASPD-P). However, the underlying mechanisms for such differences are poorly understood, hampering progress in the development of drug treatments for this population. Intranasal oxytocin (OT) has garnered significant attention due to its prosocial effects in healthy individuals. We sought to establish the impact of OT on resting-state brain function in individuals with ASPD, and to explore whether modulation differs between individuals with and without psychopathy. We used arterial spin labelling (ASL) to measure regional cerebral blood flow (rCBF) to investigate brain function at rest and modulation of key disease-targets by a single acute dose of OT (40 IU). We used a double-blind, placebo-controlled, crossover design in males with a history of violent offending with ASPD+P (N = 17) or ASPD-P (N = 14) and a group of healthy male non-offenders (N = 22). Both ASPD subtypes showed reduced rCBF in frontotemporal regions compared to non-offenders. However, those with ASPD+P demonstrated significantly greater rCBF increases in posterior default mode network regions compared to those with ASPD-P. OT administration selectively reduced rCBF in the left basal ganglia of the ASPD-P group, an effect not observed in the ASPD+P or non-offender groups. Our results provide further evidence of functional brain differences between ASPD+P and ASPD-P groups, and a differential modulating effect of oxytocin. The neurobiological distinctions between ASPD+P and ASPD-P groups are important considerations for future therapeutic developments.
Open AccessResting-state brain function and its modulation by intranasal oxytocin in antisocial personality disorder with and without psychopathy
Behavioural, structural and functional neuroimaging differences have been demonstrated between individuals with antisocial personality disorder with (ASPD+P) or without psychopathy (ASPD-P). However, the underlying mechanisms for such differences are poorly understood, hampering progress in the development of drug treatments for this population. Intranasal oxytocin (OT) has garnered significant attention due to its prosocial effects in healthy individuals. We sought to establish the impact of OT on resting-state brain function in individuals with ASPD, and to explore whether modulation differs between individuals with and without psychopathy. We used arterial spin labelling (ASL) to measure regional cerebral blood flow (rCBF) to investigate brain function at rest and modulation of key disease-targets by a single acute dose of OT (40 IU). We used a double-blind, placebo-controlled, crossover design in males with a history of violent offending with ASPD+P (N = 17) or ASPD-P (N = 14) and a group of healthy male non-offenders (N = 22). Both ASPD subtypes showed reduced rCBF in frontotemporal regions compared to non-offenders. However, those with ASPD+P demonstrated significantly greater rCBF increases in posterior default mode network regions compared to those with ASPD-P. OT administration selectively reduced rCBF in the left basal ganglia of the ASPD-P group, an effect not observed in the ASPD+P or non-offender groups. Our results provide further evidence of functional brain differences between ASPD+P and ASPD-P groups, and a differential modulating effect of oxytocin. The neurobiological distinctions between ASPD+P and ASPD-P groups are important considerations for future therapeutic developments.
- Open Access
The oxytocin system in patients with craniopharyngioma: A systematic review
Craniopharyngioma is a benign tumour affecting the hypothalamic and pituitary regions, which are involved in the production and secretion of oxytocin. We conducted a systematic review to assess dysregulation of the oxytocin system in craniopharyngioma and associations with neurobehavioural, eating, and metabolic abnormalities. Eight studies (n=72 patients) were included. Evidence for dysfunction of the endogenous oxytocin system in craniopharyngioma is limited and mixed. While no significant differences in baseline salivary oxytocin concentrations were reported between patients with craniopharyngioma and controls, patients with craniopharyngioma were found to have blunted salivary oxytocin response following exercise stimulation and this was associated with greater state anxiety and higher BMI. Studies administering exogenous oxytocin are sparse and do not meet required standards. Hypothalamic damage may pose an additional mechanism of oxytocin dysregulation. Improving understanding of the oxytocin system in craniopharyngioma could be pivotal for exploring the potential therapeutic role of exogenous oxytocin in this condition.
Open AccessThe oxytocin system in patients with craniopharyngioma: A systematic review
Craniopharyngioma is a benign tumour affecting the hypothalamic and pituitary regions, which are involved in the production and secretion of oxytocin. We conducted a systematic review to assess dysregulation of the oxytocin system in craniopharyngioma and associations with neurobehavioural, eating, and metabolic abnormalities. Eight studies (n=72 patients) were included. Evidence for dysfunction of the endogenous oxytocin system in craniopharyngioma is limited and mixed. While no significant differences in baseline salivary oxytocin concentrations were reported between patients with craniopharyngioma and controls, patients with craniopharyngioma were found to have blunted salivary oxytocin response following exercise stimulation and this was associated with greater state anxiety and higher BMI. Studies administering exogenous oxytocin are sparse and do not meet required standards. Hypothalamic damage may pose an additional mechanism of oxytocin dysregulation. Improving understanding of the oxytocin system in craniopharyngioma could be pivotal for exploring the potential therapeutic role of exogenous oxytocin in this condition.
- Open Access
- 19 January 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 29 (5) , 1241-1252
Connectome dysfunction in patients at clinical high risk for psychosis and modulation by oxytocin
Abnormalities in functional brain networks (functional connectome) are increasingly implicated in people at Clinical High Risk for Psychosis (CHR-P). Intranasal oxytocin, a potential novel treatment for the CHR-P state, modulates network topology in healthy individuals. However, its connectomic effects in people at CHR-P remain unknown. Forty-seven men (30 CHR-P and 17 healthy controls) received acute challenges of both intranasal oxytocin 40 IU and placebo in two parallel randomised, double-blind, placebo-controlled cross-over studies which had similar but not identical designs. Multi-echo resting-state fMRI data was acquired at approximately 1 h post-dosing. Using a graph theoretical approach, the effects of group (CHR-P vs healthy control), treatment (oxytocin vs placebo) and respective interactions were tested on graph metrics describing the topology of the functional connectome. Group effects were observed in 12 regions (all pFDR < 0.05) most localised to the frontoparietal network. Treatment effects were found in 7 regions (all pFDR < 0.05) predominantly within the ventral attention network. Our major finding was that many effects of oxytocin on network topology differ across CHR-P and healthy individuals, with significant interaction effects observed in numerous subcortical regions strongly implicated in psychosis onset, such as the thalamus, pallidum and nucleus accumbens, and cortical regions which localised primarily to the default mode network (12 regions, all pFDR < 0.05). Collectively, our findings provide new insights on aberrant functional brain network organisation associated with psychosis risk and demonstrate, for the first time, that oxytocin modulates network topology in brain regions implicated in the pathophysiology of psychosis in a clinical status (CHR-P vs healthy control) specific manner.
- 19 January 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 29 (5) , 1241-1252
Open AccessConnectome dysfunction in patients at clinical high risk for psychosis and modulation by oxytocin
Abnormalities in functional brain networks (functional connectome) are increasingly implicated in people at Clinical High Risk for Psychosis (CHR-P). Intranasal oxytocin, a potential novel treatment for the CHR-P state, modulates network topology in healthy individuals. However, its connectomic effects in people at CHR-P remain unknown. Forty-seven men (30 CHR-P and 17 healthy controls) received acute challenges of both intranasal oxytocin 40 IU and placebo in two parallel randomised, double-blind, placebo-controlled cross-over studies which had similar but not identical designs. Multi-echo resting-state fMRI data was acquired at approximately 1 h post-dosing. Using a graph theoretical approach, the effects of group (CHR-P vs healthy control), treatment (oxytocin vs placebo) and respective interactions were tested on graph metrics describing the topology of the functional connectome. Group effects were observed in 12 regions (all pFDR < 0.05) most localised to the frontoparietal network. Treatment effects were found in 7 regions (all pFDR < 0.05) predominantly within the ventral attention network. Our major finding was that many effects of oxytocin on network topology differ across CHR-P and healthy individuals, with significant interaction effects observed in numerous subcortical regions strongly implicated in psychosis onset, such as the thalamus, pallidum and nucleus accumbens, and cortical regions which localised primarily to the default mode network (12 regions, all pFDR < 0.05). Collectively, our findings provide new insights on aberrant functional brain network organisation associated with psychosis risk and demonstrate, for the first time, that oxytocin modulates network topology in brain regions implicated in the pathophysiology of psychosis in a clinical status (CHR-P vs healthy control) specific manner.
- Open Access
- 25 July 2023
- Published by Springer Nature in Molecular Autism
- Vol. 14 (1) , 1-14
Neurodevelopmental impairments in children with septo-optic dysplasia spectrum conditions: a systematic review
Background: Septo-optic dysplasia (SOD) is a rare condition diagnosed in children with two or more of the following: hypopituitarism, midline brain abnormalities, and optic nerve hypoplasia. Children with SOD experience varied visual impairment and endocrine dysfunction. Autistic-like behaviours have been reported; however, their nature and prevalence remain to be fully understood. The present systematic review aimed to explore the type and prevalence of neurodevelopmental impairments in children with SOD spectrum conditions. Methods: The search was conducted in PubMed, EMBASE, and PsycInfo. Hand-searching reference lists of included studies was conducted. All peer-reviewed, observational studies assessing behavioural and cognitive impairments or autism spectrum disorder (ASD) symptoms in children (< 18 years) with SOD, optic nerve hypoplasia, and SOD-plus were included. Studies were excluded if they did not report standardised measures of neurodevelopmental impairments or ASD outcomes. Results: From 2132 screened articles, 20 articles reporting data from a total of 479 children were included in prevalence estimates. Of 14 studies assessing cognitive-developmental outcomes, 175 of 336 (52%) children presented with intellectual disability or developmental delay. A diagnosis of ASD or clinical level of symptoms was observed in 65 of 187 (35%) children across five studies. Only five studies assessed for dysfunction across behavioural, emotional, or social domains and reported impairments in 88 of 184 (48%) of children assessed. Limitations: Importantly, high heterogeneity among the samples in relation to their neuroanatomical, endocrine, and optic nerve involvement meant that it was not possible to statistically assess the relative contribution of these confounding factors to the specific neurodevelopmental phenotype. This was further limited by the variation in study designs and behavioural assessments used across the included studies, which may have increased the risk of information bias. Conclusions: This systematic review suggests that the prevalence of neurodevelopmental impairments in children within the SOD spectrum may be high. Clinicians should therefore consider including formal assessments of ASD symptoms and neurodevelopmental impairments alongside routine care. There is, additionally, a need for further research to define and validate a standardised battery of tools that accurately identify neurodevelopmental impairments in SOD spectrum conditions, and for research to identify the likely causal mechanisms.
- 25 July 2023
- Published by Springer Nature in Molecular Autism
- Vol. 14 (1) , 1-14
Open AccessNeurodevelopmental impairments in children with septo-optic dysplasia spectrum conditions: a systematic review
Background: Septo-optic dysplasia (SOD) is a rare condition diagnosed in children with two or more of the following: hypopituitarism, midline brain abnormalities, and optic nerve hypoplasia. Children with SOD experience varied visual impairment and endocrine dysfunction. Autistic-like behaviours have been reported; however, their nature and prevalence remain to be fully understood. The present systematic review aimed to explore the type and prevalence of neurodevelopmental impairments in children with SOD spectrum conditions. Methods: The search was conducted in PubMed, EMBASE, and PsycInfo. Hand-searching reference lists of included studies was conducted. All peer-reviewed, observational studies assessing behavioural and cognitive impairments or autism spectrum disorder (ASD) symptoms in children (< 18 years) with SOD, optic nerve hypoplasia, and SOD-plus were included. Studies were excluded if they did not report standardised measures of neurodevelopmental impairments or ASD outcomes. Results: From 2132 screened articles, 20 articles reporting data from a total of 479 children were included in prevalence estimates. Of 14 studies assessing cognitive-developmental outcomes, 175 of 336 (52%) children presented with intellectual disability or developmental delay. A diagnosis of ASD or clinical level of symptoms was observed in 65 of 187 (35%) children across five studies. Only five studies assessed for dysfunction across behavioural, emotional, or social domains and reported impairments in 88 of 184 (48%) of children assessed. Limitations: Importantly, high heterogeneity among the samples in relation to their neuroanatomical, endocrine, and optic nerve involvement meant that it was not possible to statistically assess the relative contribution of these confounding factors to the specific neurodevelopmental phenotype. This was further limited by the variation in study designs and behavioural assessments used across the included studies, which may have increased the risk of information bias. Conclusions: This systematic review suggests that the prevalence of neurodevelopmental impairments in children within the SOD spectrum may be high. Clinicians should therefore consider including formal assessments of ASD symptoms and neurodevelopmental impairments alongside routine care. There is, additionally, a need for further research to define and validate a standardised battery of tools that accurately identify neurodevelopmental impairments in SOD spectrum conditions, and for research to identify the likely causal mechanisms.
- Open Access
Connectome dysfunction in patients at clinical high risk for psychosis and modulation by oxytocin
Abnormalities in functional brain networks (functional connectome) are increasingly implicated in people at Clinical High Risk for Psychosis (CHR-P). Intranasal oxytocin, a potential novel treatment for the CHR-P state, modulates network topology in healthy individuals. However, its connectomic effects in people at CHR-P remain unknown. Forty-seven men (30 CHR-P and 17 healthy controls) received acute challenges of both intranasal oxytocin 40 IU and placebo in two parallel randomised, double-blind, placebo-controlled cross-over studies. Multi-echo resting-state fMRI data was acquired at approximately 1h post-dosing. Using a graph theoretical approach, the effects of group (CHR-P vs healthy control), treatment (oxytocin vs placebo) and respective interactions were tested on graph metrics describing the topology of the functional connectome. Group effects were observed in 12 regions (all p FDR <.05) most localised to the frontoparietal network. Treatment effects were found in 7 regions (all p FDR <.05) predominantly within the ventral attention network. Our major finding was that many effects of oxytocin on network topology differ across CHR-P and healthy individuals, with significant interaction effects observed in numerous subcortical regions strongly implicated in psychosis onset, such as the thalamus, pallidum and nucleus accumbens, and cortical regions which localised primarily to the default mode network (12 regions, all p FDR <.05). Our findings provide new insights on aberrant functional brain network organisation associated with psychosis risk and demonstrate, for the first time, that oxytocin modulates network topology in brain regions implicated in the pathophysiology of psychosis in a clinical status (CHR-P vs healthy control) specific manner. Further profiling of the connectomic, clinical and cognitive effects of oxytocin in this population is warranted.
Open AccessConnectome dysfunction in patients at clinical high risk for psychosis and modulation by oxytocin
Abnormalities in functional brain networks (functional connectome) are increasingly implicated in people at Clinical High Risk for Psychosis (CHR-P). Intranasal oxytocin, a potential novel treatment for the CHR-P state, modulates network topology in healthy individuals. However, its connectomic effects in people at CHR-P remain unknown. Forty-seven men (30 CHR-P and 17 healthy controls) received acute challenges of both intranasal oxytocin 40 IU and placebo in two parallel randomised, double-blind, placebo-controlled cross-over studies. Multi-echo resting-state fMRI data was acquired at approximately 1h post-dosing. Using a graph theoretical approach, the effects of group (CHR-P vs healthy control), treatment (oxytocin vs placebo) and respective interactions were tested on graph metrics describing the topology of the functional connectome. Group effects were observed in 12 regions (all p FDR <.05) most localised to the frontoparietal network. Treatment effects were found in 7 regions (all p FDR <.05) predominantly within the ventral attention network. Our major finding was that many effects of oxytocin on network topology differ across CHR-P and healthy individuals, with significant interaction effects observed in numerous subcortical regions strongly implicated in psychosis onset, such as the thalamus, pallidum and nucleus accumbens, and cortical regions which localised primarily to the default mode network (12 regions, all p FDR <.05). Our findings provide new insights on aberrant functional brain network organisation associated with psychosis risk and demonstrate, for the first time, that oxytocin modulates network topology in brain regions implicated in the pathophysiology of psychosis in a clinical status (CHR-P vs healthy control) specific manner. Further profiling of the connectomic, clinical and cognitive effects of oxytocin in this population is warranted.
- 6 March 2023
- Published by Elsevier in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
- Vol. 8 (3) , 233-234
Using Multivariate Neurofunctional Signatures to Dissect the Specific Mental Processes Modulated by Novel Pharmacological Targets
- 6 March 2023
- Published by Elsevier in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
- Vol. 8 (3) , 233-234
Using Multivariate Neurofunctional Signatures to Dissect the Specific Mental Processes Modulated by Novel Pharmacological Targets
- Open Access
- 31 March 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-4
Author Correction: Effects of route of administration on oxytocin-induced changes in regional cerebral blood flow in humans
- 31 March 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-4
Open AccessAuthor Correction: Effects of route of administration on oxytocin-induced changes in regional cerebral blood flow in humans
- 3 March 2022
- Published by Elsevier in Progress in Neurobiology
- Vol. 213, 102253
Oxytocin modulates neurocomputational mechanisms underlying prosocial reinforcement learning
- 3 March 2022
- Published by Elsevier in Progress in Neurobiology
- Vol. 213, 102253
Oxytocin modulates neurocomputational mechanisms underlying prosocial reinforcement learning